[go: up one dir, main page]

NO20015063D0 - En oral formulering for administrering til ileum omfattende en inhibitorforbindelse til ileal-gallesyre transporten - Google Patents

En oral formulering for administrering til ileum omfattende en inhibitorforbindelse til ileal-gallesyre transporten

Info

Publication number
NO20015063D0
NO20015063D0 NO20015063A NO20015063A NO20015063D0 NO 20015063 D0 NO20015063 D0 NO 20015063D0 NO 20015063 A NO20015063 A NO 20015063A NO 20015063 A NO20015063 A NO 20015063A NO 20015063 D0 NO20015063 D0 NO 20015063D0
Authority
NO
Norway
Prior art keywords
inhibitor compound
bile acid
ileum
ileal
administration
Prior art date
Application number
NO20015063A
Other languages
English (en)
Other versions
NO20015063L (no
Inventor
Bertil Abrahamsson
Ann-Margret Lindqvist
Anna-Lena Ungell
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20015063L publication Critical patent/NO20015063L/no
Publication of NO20015063D0 publication Critical patent/NO20015063D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20015063A 1999-04-19 2001-10-18 En oral formulering for administrering til ileum omfattende en inhibitorforbindelse til ileal-gallesyre transporten NO20015063D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9901387A SE9901387D0 (sv) 1999-04-19 1999-04-19 New pharmaceutical foromaulations
PCT/SE2000/000755 WO2000062810A1 (en) 1999-04-19 2000-04-19 An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport

Publications (2)

Publication Number Publication Date
NO20015063L NO20015063L (no) 2001-10-18
NO20015063D0 true NO20015063D0 (no) 2001-10-18

Family

ID=20415263

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015063A NO20015063D0 (no) 1999-04-19 2001-10-18 En oral formulering for administrering til ileum omfattende en inhibitorforbindelse til ileal-gallesyre transporten

Country Status (27)

Country Link
EP (1) EP1173205B1 (no)
JP (1) JP2002542208A (no)
KR (1) KR20010108516A (no)
CN (1) CN1348384A (no)
AT (1) ATE296641T1 (no)
AU (1) AU767425B2 (no)
BR (1) BR0009835A (no)
CA (1) CA2379105A1 (no)
CZ (1) CZ20013743A3 (no)
DE (1) DE60020551T2 (no)
DK (1) DK1173205T3 (no)
EE (1) EE04607B1 (no)
ES (1) ES2241603T3 (no)
HK (1) HK1042850A1 (no)
HU (1) HUP0200793A3 (no)
IL (1) IL145871A0 (no)
IS (1) IS2161B (no)
NO (1) NO20015063D0 (no)
NZ (1) NZ514264A (no)
PL (1) PL351186A1 (no)
PT (1) PT1173205E (no)
SE (1) SE9901387D0 (no)
SI (1) SI1173205T1 (no)
SK (1) SK15282001A3 (no)
TR (1) TR200103033T2 (no)
WO (1) WO2000062810A1 (no)
ZA (1) ZA200108539B (no)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
PL201766B1 (pl) * 2001-01-31 2009-05-29 Roehm Gmbh Wielocząsteczkowa postać leku zawierająca przynajmniej dwa typy granulek powlekanych w odmienny sposób oraz jej zastosowanie
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
ES2278045T3 (es) 2001-09-08 2007-08-01 Astrazeneca Ab Derivados benzotiazepinicos y benzotiadiazepinicos con actividad inhibidora del transporte de acidos biliares del ileon (ibat) para el tratamiento de hiperlipidemia.
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
GB0216321D0 (en) * 2002-07-13 2002-08-21 Astrazeneca Ab Therapeutic treatment
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
JP2011520914A (ja) 2008-05-15 2011-07-21 トランスモレキュラー， インコーポレイテッド 転移腫瘍の処置
EP2364161B1 (en) 2008-11-26 2020-03-11 Satiogen Pharmaceuticals, Inc. Compositions containing satiogens and methods of use
US9339480B2 (en) 2008-11-26 2016-05-17 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
GB0900350D0 (en) * 2009-01-09 2009-02-11 Cambridge Entpr Ltd Formulations of viable bacteria for oral delivery
CN106995493B (zh) 2010-02-04 2021-09-24 卫材公司 氯毒素多肽和结合物及其应用
ES2601182T3 (es) 2010-05-11 2017-02-14 Fred Hutchinson Cancer Research Center Variantes de clorotoxina, conjugados y métodos para su utilización
WO2011150286A2 (en) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals,Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
EP3400944B1 (en) 2010-11-04 2020-07-15 Albireo AB Ibat inhibitors for the treatment of liver diseases
DK2637646T3 (en) * 2010-11-08 2016-08-29 Albireo Ab PHARMACEUTICAL COMBINATION CONTAINING AN IBAT inhibitor and a bile acid binder
KR102051030B1 (ko) * 2011-10-28 2019-12-02 루메나 파마수티컬즈, 인코포레이티드 소아 담즙울체성 간 질환 치료용 담즙산 재순환 억제제
MX363161B (es) 2011-10-28 2019-03-13 Lumena Pharmaceuticals Inc Inhibidores de la recirculación de ácidos biliares para el tratamiento de hipercolemia y enfermedad hepática colestásica.
CN105189540A (zh) 2012-12-10 2015-12-23 弗莱德哈钦森癌症研究中心 含脂质运载蛋白融合伴侣
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
JP6751020B2 (ja) 2014-06-25 2020-09-02 Ｅａファーマ株式会社 固形製剤及びその着色防止又は着色低減方法
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
CN105362244A (zh) * 2015-11-26 2016-03-02 青岛海之源智能技术有限公司 考来烯胺缓释片及制备方法
CN108601744B (zh) 2016-02-09 2022-01-04 阿尔比里奥公司 口服考来烯胺制剂及其用途
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
JP6954927B2 (ja) 2016-02-09 2021-10-27 アルビレオ・アクチボラグ 経口コレスチラミン製剤及びその使用
WO2017181149A1 (en) 2016-04-15 2017-10-19 Blaze Bioscience, Inc. Methods of treating breast cancer
CN110996915B (zh) 2017-08-09 2023-10-03 阿尔比里奥公司 考来烯胺丸粒、口服考来烯胺制剂及其用途
CN111032019B (zh) 2017-08-09 2022-07-05 阿尔比里奥公司 考来烯胺颗粒、口服考来烯胺制剂及其用途
WO2019234077A1 (en) 2018-06-05 2019-12-12 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CA3100691A1 (en) 2018-06-20 2019-12-26 Albireo Ab Crystal modifications of odevixibat
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
EP3921028B1 (en) 2019-02-06 2022-11-09 Albireo AB Benzothiadiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
WO2020161216A1 (en) 2019-02-06 2020-08-13 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
AU2020223022A1 (en) 2019-02-12 2021-09-02 Mirum Pharmaceuticals, Inc. Methods for increasing growth in pediatric subjects having cholestatic liver disease
MX2022001865A (es) 2019-08-12 2022-03-11 Massachusetts Inst Technology Articulos y metodos para la administracion de agentes terapeuticos.
AR120679A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar
WO2021110887A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
WO2021110885A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
AR120676A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como ácido biliar
CA3158184A1 (en) 2019-12-04 2021-08-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CN114761079B (zh) 2019-12-04 2024-05-28 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
JP2023504647A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
AR120683A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como ácido biliar
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
EP4188541B1 (en) 2020-08-03 2024-12-25 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
CA3196488A1 (en) 2020-11-12 2022-05-19 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
JP2024500309A (ja) 2020-12-04 2024-01-09 アルビレオ エービー ベンゾチア（ジ）アゼピン化合物および胆汁酸モジュレータとしてのその使用
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
WO2023203248A1 (en) 2022-04-22 2023-10-26 Albireo Ab Subcutaneous administration of an asbt inhibitor
CN119343140A (zh) 2022-06-09 2025-01-21 阿尔比里奥公司 治疗肝炎
CN119487013A (zh) 2022-07-05 2025-02-18 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
US20240207286A1 (en) 2022-12-09 2024-06-27 Albireo Ab Asbt inhibitors in the treatment of renal diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA941003B (en) * 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
TW289020B (no) * 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
JPH07223970A (ja) * 1994-02-10 1995-08-22 Tanabe Seiyaku Co Ltd 消化管内適所放出製剤

Also Published As

Publication number Publication date
TR200103033T2 (tr) 2002-03-21
WO2000062810A1 (en) 2000-10-26
PL351186A1 (en) 2003-03-24
HK1042850A1 (en) 2002-08-30
NO20015063L (no) 2001-10-18
IS2161B (is) 2006-11-15
IS6109A (is) 2001-10-16
EE04607B1 (et) 2006-04-17
IL145871A0 (en) 2002-07-25
KR20010108516A (ko) 2001-12-07
ES2241603T3 (es) 2005-11-01
SE9901387D0 (sv) 1999-04-19
AU767425B2 (en) 2003-11-13
BR0009835A (pt) 2002-01-08
HUP0200793A3 (en) 2004-07-28
HUP0200793A2 (hu) 2002-07-29
SK15282001A3 (sk) 2002-04-04
PT1173205E (pt) 2005-10-31
SI1173205T1 (en) 2005-10-31
NZ514264A (en) 2003-10-31
EP1173205B1 (en) 2005-06-01
JP2002542208A (ja) 2002-12-10
EE200100545A (et) 2003-02-17
ATE296641T1 (de) 2005-06-15
ZA200108539B (en) 2003-01-17
DE60020551T2 (de) 2006-03-23
EP1173205A1 (en) 2002-01-23
AU4633500A (en) 2000-11-02
CA2379105A1 (en) 2000-10-26
CZ20013743A3 (cs) 2002-01-16
DK1173205T3 (da) 2005-08-08
CN1348384A (zh) 2002-05-08
DE60020551D1 (de) 2005-07-07

Similar Documents

Publication Publication Date Title
NO20015063L (no) En oral formulering for administrering til ileum omfattende en inhibitorforbindelse til ileal-gallesyre transporten
SE0003766D0 (sv) Novel formulation
NZ514574A (en) Novel method of treatment
BG105568A (en) Pharmaceutical compositions for modified release of an insulin sensitiser and another antidiabetic agent
HUP9803044A2 (hu) Ibuprofentartalmú készítmény
CA2301017A1 (en) Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
EE200200086A (et) Reniin-angiotensiini süsteemi inhibiitori kasutamine, kombineeritud produkt ja meetod kardiovaskulaarsete haigusjuhtude ärahoidmiseks
EP1545621A4 (en) CARRIER
NO20001673L (no) Farmasøytiske blandinger for oral administrering av molekylært jod
DE60030283D1 (de) Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
BG105570A (en) Pharmaceutical compositions for modified release insulin sensitiser
TW349865B (en) Therapeutic agent for hemorrhoidal diseases
MY135646A (en) Indolyl derivatives
YU66202A (sh) Sistem za kontrolisano otpuštanje ciprofloksacina nakon oralne primene u jednoj dnevnoj dozi
JP2002500181A5 (no)
WO2002069968A8 (en) New use
EP1347754A4 (en) COMPOSITIONS FOR PREVENTION OF ADHESION
BG104692A (en) Extended release tiagabine formulation
DE69814669D1 (de) Pharmaceutische Zusammensetzung enthaltend (+)-EPHEDRIN und einen H1 Rezeptor Antagonisten
AP1692A (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent.
AU4918900A (en) Interferon-beta use in the treatment of ewing's family of tumors
UA4313U (uk) Спосіб лікування системного червоного вовчака
MY132962A (en) Inotropic agents with negative chronotropic and vasodilatory effects
TR200102245T2 (tr) Koroner müdahale ile ilgili kardiovasküler olayların önlenmesi veya azaltılması için yöntem.
UA39418A (uk) Спосіб лікування виразкової хвороби, асоційованої з helicobacter pylori

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application